BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Novo Nordisk readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Novo Nordisk's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07184632-138@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:NNC0662-0419: Phase 2 readout est. (NCT07184632)
DESCRIPTION:NNC0662-0419\, phase 2\, Obesity.\nStudy: A Research Study on H
 ow Well Different Doses of the Medicine NNC0662-0419 Help People Living Wi
 th Overweight or Obesity\nEstimated primary completion: 14 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nnc0662-0419#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07184632
URL:https://assetmemo.bio/drug/nnc0662-0419#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395687-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:UBT251: Phase 2 readout est. (NCT07395687)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: A Research Study on How Wel
 l Different Doses of the Medicine UBT251 Help People Living With Overweigh
 t or Obesity\nEstimated primary completion: 14 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07395687
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076199-319@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Awiqli (insulin icodec): Phase 3 readout est. (NCT07076199)
DESCRIPTION:Awiqli (insulin icodec)\, phase 3.\nStudy: A Research Study to 
 See How a Weekly Insulin\, Insulin Icodec\, Helps in Reducing the Blood Su
 gar Compared to Daily Insulin Glargine\, Both in Combination With Insulin 
 Aspart\, in Adults With Type 1 Diabetes\nEstimated primary completion: 25 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/insulin
 -icodec#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07076199
URL:https://assetmemo.bio/drug/insulin-icodec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118281-606@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Ziltivekimab: Phase 3 readout est. (NCT06118281)
DESCRIPTION:Ziltivekimab\, phase 3.\nStudy: ARTEMIS - A Research Study to L
 ook at How Ziltivekimab Works Compared to Placebo in People With a Heart A
 ttack\nEstimated primary completion: 29 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ziltivekimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06118281
URL:https://assetmemo.bio/drug/ziltivekimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011667-121@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0701
 1667)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Well CagriSema Helps People Living With
  Obesity Lose Weight and Maintain Weight Loss in the Long-term\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07011667
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220642-120@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220642)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity Following Treatment With Cagrilintide\n
 Estimated primary completion: 11 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cagrilintide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07220642
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220759-120@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220759)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity and Type 2 Diabetes Following Treatment
  With Cagrilintide\nEstimated primary completion: 12 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220759
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979375-598@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270516
DTEND;VALUE=DATE:20270517
SUMMARY:CDR132L: Phase 2 readout est. (NCT06979375)
DESCRIPTION:CDR132L\, phase 2\, Heart Failure.\nStudy: A Research Study Com
 paring CDR132L With Placebo on the Structure and Function of the Heart in 
 People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction an
 d Left Ventricular Hypertrophy\nEstimated primary completion: 16 May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cdr132l#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06979375
URL:https://assetmemo.bio/drug/cdr132l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745504-120@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07745504)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study to C
 ompare Two Different Versions of Injectable Cagrilintide and Placebo in Pe
 ople With Excess Body Weight\nEstimated primary completion: 18 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07745504
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145151-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270604
DTEND;VALUE=DATE:20270605
SUMMARY:UBT251: Phase 2 readout est. (NCT07145151)
DESCRIPTION:UBT251\, phase 2.\nStudy: A Study of UBT251 in Participants Wit
 h Metabolic Dysfunction-Associated Steatohepatitis (MASH)\nEstimated prima
 ry completion: 4 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ubt251#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07145151
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817251-121@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0781
 7251)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: Research Study on How People With Type 2 Diabetes Tolerate Swit
 ching From Semaglutide to Cagrisema\nEstimated primary completion: 9 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-se
 maglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07817251
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639021-138@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:NNC0662-0419: Phase 2 readout est. (NCT07639021)
DESCRIPTION:NNC0662-0419\, phase 2\, Obesity.\nStudy: A Research Study Comp
 aring Different Ways of Increasing the Dose of NNC0662-0419 in Participant
 s With Obesity\nEstimated primary completion: 14 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nnc0662-0419#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07639021
URL:https://assetmemo.bio/drug/nnc0662-0419#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05953584-10273@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Etavopivat: Phase 2 readout est. (NCT05953584)
DESCRIPTION:Etavopivat\, phase 2\, Sickle Cell Disease.\nStudy: A Phase 2 O
 pen-label Study to Evaluate the Activity of Etavopivat on Transcranial Dop
 pler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at 
 Increased Risk for Primary Stroke\nEstimated primary completion: 20 August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595358
 4
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612268-10273@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06612268)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate How Well Etavopivat Works in People With Sickle Cell Disease\nEst
 imated primary completion: 27 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/etavopivat#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06612268
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415954-138@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:NNC0662-0419: Phase 2 readout est. (NCT07415954)
DESCRIPTION:NNC0662-0419\, phase 2\, Type 2 Diabetes.\nStudy: A Research St
 udy Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower 
 Blood Sugar in People With Type 2 Diabetes\nEstimated primary completion: 
 3 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nnc
 0662-0419#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07415954
URL:https://assetmemo.bio/drug/nnc0662-0419#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659574-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:UBT251: Phase 3 readout est. (NCT07659574)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate
  Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）\nEstimated pr
 imary completion: 24 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ubt251#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07659574
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648225-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:UBT251: Phase 3 readout est. (NCT07648225)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (Overweight or Obesity)\nEstimated primary completion: 29 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07648225
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668388-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:UBT251: Phase 2 readout est. (NCT07668388)
DESCRIPTION:UBT251\, phase 2\, Type 2 Diabetes.\nStudy: A Research Study Co
 mparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar 
 in People With Type 2 Diabetes\nEstimated primary completion: 4 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07668388
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03811561-114@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271107
DTEND;VALUE=DATE:20271108
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT03811561)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: A Re
 search Study to Look at How Semaglutide Compared to Placebo Affects Diabet
 ic Eye Disease in People With Type 2 Diabetes\nEstimated primary completio
 n: 7 November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03811561
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979362-598@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:CDR132L: Phase 2 readout est. (NCT06979362)
DESCRIPTION:CDR132L\, phase 2\, Heart Failure.\nStudy: A Research Study Com
 paring Different Doses of CDR132L With Placebo on the Structure and Functi
 on of the Heart in People With Heart Failure With Preserved Ejection Fract
 ion and Left Ventricular Hypertrophy\nEstimated primary completion: 16 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cdr132l#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979
 362
URL:https://assetmemo.bio/drug/cdr132l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770841-11055@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Semaglutide (Wegovy tablets): Phase 3 readout est. (NCT07770841)
DESCRIPTION:Semaglutide (Wegovy tablets)\, phase 3\, Obesity.\nStudy: Resea
 rch Study on How Well Oral Semaglutide Works for Weight Loss in Adults Wit
 h Excess Body Weight\nEstimated primary completion: 22 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy-tablet
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 770841
URL:https://assetmemo.bio/drug/semaglutide-wegovy-tablets#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06198712-10273@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:Etavopivat: Phase 2 readout est. (NCT06198712)
DESCRIPTION:Etavopivat\, phase 2\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patien
 ts With Sickle Cell Disease\nEstimated primary completion: 23 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06198712
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564414-121@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0756
 4414)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Two Different Doses of CagriSema and On
 e Dose of Semaglutide Help People Living With Obesity With or Without Type
  2 Diabetes Lose Weight\nEstimated primary completion: 23 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-semagluti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7564414
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260709-634@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Coramitug: Phase 2 readout est. (NCT06260709)
DESCRIPTION:Coramitug\, phase 2\, Heart Failure.\nStudy: A Research Study t
 o Look at Long-term Treatment With a Medicine Called NNC6019-0001 for Peop
 le Who Have Heart Failure Due to Transthyretin Amyloidosis\nEstimated prim
 ary completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/coramitug#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06260709
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653477-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:UBT251: Phase 3 readout est. (NCT07653477)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic
  Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
 \nEstimated primary completion: 29 February 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07653477
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919405-121@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0791
 9405)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Investigate How Well the Medicine CagriSema Lowers 
 High Blood Pressure in People Living With High Blood Pressure and Obesity\
 nEstimated primary completion: 1 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07919405
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931495-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931495)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight C
 ompared to Placebo in People With Type 2 Diabetes Treated With Diet and Ex
 ercise\nEstimated primary completion: 5 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07931495
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503210-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07503210)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 12: A Research S
 tudy Investigating How Well the Medicine NNC0487-0111 Helps People With Ex
 cess Body Weight Maintain Their Weight Loss\nEstimated primary completion:
  6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagam
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07503210
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571109-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07571109)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 4: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway 
 Pressure Lose Weight and Improve Sleep Apnoea\nEstimated primary completio
 n: 26 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zena
 gamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07571109
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720271-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07720271)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 9: A Research St
 udy Investigating How Well Zenagamtide Tablets Help People With Excess Bod
 y Weight Lose Weight\nEstimated primary completion: 27 June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07720271
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931573-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931573)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: AMBITION 3: A 
 Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lo
 wers Blood Sugar and Body Weight Compared to Semaglutide in People With Ty
 pe 2 Diabetes Treated With Metformin\, SGLT2i\, or Both\nEstimated primary
  completion: 4 July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zenagamtide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07931573
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571005-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280712
DTEND;VALUE=DATE:20280713
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07571005)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 3: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Air
 way Pressure Lose Weight and Improve Sleep Apnoea\nEstimated primary compl
 etion: 12 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zenagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07571005
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931599-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931599)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Su
 gar and Body Weight Compared to Semaglutide at Lower Dose Levels in People
  With Type 2 Diabetes Treated With Metformin\, Sodium-Glucose Cotransporte
 r 2 Inhibitors (SGLT2i)\, or Both\nEstimated primary completion: 24 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07931599
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931547-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931547)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight C
 ompared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disea
 se Treated With Once Daily Basal Insulin Alone or in Combination With Metf
 ormin\, SGLT2i\, or Both\nEstimated primary completion: 31 July 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07931547
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797335-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07797335)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: AMBITION 7: A 
 Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and B
 ody Weight Compared to Insulin Glargine in People With Type 2 Diabetes and
  Increased Risk of Diseases That Affect the Heart and Blood Vessels Treate
 d With 1-3 Other Diabetes Medications\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0779
 7335
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533175-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07533175)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 2: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Type 2 Diabetes Lose Weight\nEstimated primary complet
 ion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 enagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07533175
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481630-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07481630)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study Inves
 tigating How Well the Medicine NNC0487-0111 Helps People With Excess Body 
 Weight and Knee Osteoarthritis Lose Weight and Reduce Pain\nEstimated prim
 ary completion: 14 August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07481630
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509307-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07509307)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 6: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain\nEstim
 ated primary completion: 14 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07509307
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767942-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:UBT251: Phase 3 readout est. (NCT07767942)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (OSA-NPAP)\nEstimated primary completion: September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07767942
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668414-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07668414)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study Inves
 tigating How Well the Medicine Zenagamtide Helps People With Excess Body W
 eight Lose Weight Compared to Semaglutide\nEstimated primary completion: 1
 0 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenag
 amtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07668414
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301034-606@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Ziltivekimab: Phase 3 readout est. (NCT07301034)
DESCRIPTION:Ziltivekimab\, phase 3.\nStudy: A Research Study to Look at the
  Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart\, Comp
 ared to Placebo\, in People With a Heart Attack\nEstimated primary complet
 ion: 14 November 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ziltivekimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07301034
URL:https://assetmemo.bio/drug/ziltivekimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400107-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07400107)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 8: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Compared to Semagluti
 de Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight\nE
 stimated primary completion: 19 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07400107
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668401-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07668401)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 13: A Research S
 tudy Investigating How Well the Medicine Zenagamtide Helps People in Asia 
 With Excess Body Weight Lose Weight\nEstimated primary completion: 11 Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 68401
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822061-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290205
DTEND;VALUE=DATE:20290206
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07822061)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 10: A Research S
 tudy Investigating How Well the Medicine NNC0487-0111 Helps People in Japa
 n With Excess Body Weight Lose Weight\nEstimated primary completion: 5 Feb
 ruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7822061
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806851-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:UBT251: Phase 3 readout est. (NCT07806851)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (OSA-PAP)\nEstimated primary completion: March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07806851
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822181-11054@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290425
DTEND;VALUE=DATE:20290426
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT04822181)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, MASH / NASH.\nStudy: Research 
 Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepa
 titis (NASH)\nEstimated primary completion: 25 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04822181
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339423-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07339423)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 1: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight Lose Weight\nEstimated primary completion: 26 June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07339423
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207811-634@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:Coramitug: Phase 3 readout est. (NCT07207811)
DESCRIPTION:Coramitug\, phase 3\, Heart Failure.\nStudy: CLEOPATTRA: A Rese
 arch Study to Look at the Effects of Treatment With a Medicine Called Cora
 mitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amy
 loid (ATTR) Amyloidosis\nEstimated primary completion: 29 June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/coramitug#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07207811
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567001-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07567001)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study to Lo
 ok at How Well NNC0487-0111 Works Compared to Placebo in People With Heart
  Failure and Obesity\nEstimated primary completion: 23 July 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07567001
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282613-121@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0728
 2613)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: A Research Study to See How Much CagriSema Lowers Blood Sugar a
 nd Body Weight Compared to Placebo in Children and Adolescents With Type 2
  Diabetes\nEstimated primary completion: 7 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07282613
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253285-120@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300320
DTEND;VALUE=DATE:20300321
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07253285)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study on H
 ow Well Cagrilintide and CagriSema Work in Children and Adolescents With E
 xcess Body Weight\nEstimated primary completion: 20 March 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07253285
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134335-199@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:UBT251: Phase 2 readout est. (NCT07134335)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: UBT251 Injection Phase II C
 linical Study (CKD)\nEstimated primary completion: 11 July 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07134335
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861100-133@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300916
DTEND;VALUE=DATE:20300917
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07861100)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: A Research Study to Lo
 ok at How Well Zenagamtide Works Compared to Placebo in People With Establ
 ished Atherosclerotic Cardiovascular Disease and Either Overweight or Obes
 ity\nEstimated primary completion: 16 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07861100
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609226-10273@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06609226)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Research 
 Study Looking at Long-term Treatment With Etavopivat in People With Sickle
  Cell Disease or Thalassaemia\nEstimated primary completion: 30 December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06609226
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
